Patent rights refer to the right to exclude other people. That is the whole of it, and it is narrower than most people expect.
A patent does not give you permission to practise your own invention. It gives you the ability to stop others practising what your claims cover.
Those are different things and the gap between them has caught out a great many inventors who assumed a granted patent meant they were clear to launch.
Rights are also national, time-limited, and lost more often than kept.
What the right actually is
| Patent rights are | Patent rights are not |
|---|---|
| A right to exclude | A right to practise |
| National | Global |
| Time-limited | Perpetual |
| Defined by the claims | Defined by the description |
| Enforceable after grant | Enforceable while pending |
| Lost if fees go unpaid | Automatic once granted |
The right to exclude is negative by design. It restrains others; it does not authorise you.
The five activities
| Activity | Covered |
|---|---|
| Making | Manufacturing the claimed invention |
| Using | Operating or employing it |
| Selling | Transferring it for value |
| Offering for sale | Even without a completed sale |
| Importing | Bringing it into the country |
Each is independent. Importing an infringing product infringes even where it was manufactured lawfully in a country with no corresponding patent.
Offering for sale counts on its own. A price list or a quotation can infringe without any product changing hands.
Which is why importation matters strategically. A US patent reaches goods made abroad at the point they enter the country.
Why you can hold a patent and still infringe
Two patents can both be valid and overlap.
| Situation | Result |
|---|---|
| You patent an improvement | Valid |
| Someone else holds a patent on the base invention | Also valid |
| Your improvement requires the base | You infringe theirs |
| They cannot practise your improvement | They infringe yours |
| Practical outcome | Cross-licence, or neither ships |
Blocking patents are ordinary, not a defect. Improvement patents that cannot be practised without a licence to the underlying invention are common in every field.
Which is why a patent is not clearance. Clearance is a freedom-to-operate analysis, and it is a different exercise entirely. See freedom to operate.
Rights before grant
| Stage | Enforceable rights |
|---|---|
| Idea | None |
| Provisional filed | None — a priority date only |
| Non-provisional pending | None |
| Published at 18 months | Provisional rights, narrowly |
| Granted | Full right to exclude |
Provisional rights require actual notice and granted claims substantially identical to the published ones. In practice they rarely produce recovery.
"Patent pending" confers no rights. It signals that an application exists, which has deterrent value and no legal force. See patent is pending.
Rights are geography-specific
| Patent granted by | Rights in |
|---|---|
| USPTO | The United States only |
| EPO, then validated | Each validated state separately |
| CNIPA | China only |
| JPO | Japan only |
| Nowhere | Nowhere |
There is no world patent. The PCT is a filing route that defers national decisions; it does not grant anything.
European patents fragment at grant. Validation in each designated state creates a national right with its own annuity, so one European patent can be alive in three countries and lapsed in four.
Manufacturing jurisdictions are undervalued. Coverage where a product is made can reach the supply chain rather than chasing distribution. See patent annuity fees by country.
Duration
| Type | Term | Fees |
|---|---|---|
| Utility | 20 years from earliest non-provisional filing | Three |
| Design | 15 years from grant | None |
| Plant | 20 years from filing | None |
| Adjustment | Effect |
|---|---|
| Patent Term Adjustment | Adds days for USPTO delay |
| Patent Term Extension | Up to 5 years, regulated products |
| Terminal disclaimer | Caps the term to an earlier patent |
| Continuation chain | Runs from the earliest parent |
Continuations are the common miscalculation. A patent filed in 2024 as a continuation of a 2016 application expires in 2036, not 2044.
Check Related U.S. Application Data on the front page before calculating anything. See patent life.
Rights end more often by fee than by expiry
| Fee | Due after grant | Large | Small | Micro |
|---|---|---|---|---|
| First | 3.5 years | $2,150 | $860 | $430 |
| Second | 7.5 years | $4,040 | $1,616 | $808 |
| Third | 11.5 years | $8,280 | $3,312 | $1,656 |
| Total | $14,470 | $5,788 | $2,894 |
| Ipiry Patent Survival Curve v1.0 | Rate |
|---|---|
| Survive the 3.5-year fee (2022 cohort) | 85.8% |
| Survive the 7.5-year fee (2018 cohort) | 64.6% |
| Reach full term (2014 cohort) | 41.4% |
| Abandoned before full term | 58.6% |
Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.
Nearly three in five sets of US patent rights end early, by decision rather than by expiry.
Infringement does not require copying
| Right | Independent creation a defence? |
|---|---|
| Patent | No |
| Copyright | Yes |
| Trade secret | Yes |
| Trademark | Sometimes, on confusion analysis |
This is what makes patent rights unusually strong. A competitor that never heard of your patent and developed the same solution independently still infringes.
It also means your own independent development is no defence against someone else's patent, which is the reason freedom-to-operate work exists.
What rights do not reach
| Activity | Covered? |
|---|---|
| Making the invention abroad | Not by a US patent |
| Importing the product into the US | Yes |
| Purely private, non-commercial use | Technically covered; rarely pursued |
| Certain regulatory-approval activity | Statutory safe harbour |
| Independent invention | Covered — no defence |
| Prior commercial use, in limited cases | Possible defence |
The regulatory safe harbour matters in pharmaceuticals. Activity reasonably related to obtaining FDA approval is protected, which is what enables generic development before patent expiry.
Prior commercial use is a narrow defence, available in defined circumstances to a party that commercially used the invention before the patent's effective filing date.
Who holds them
| Situation | Initial holder |
|---|---|
| Default | The inventors |
| Employee, with a written assignment | The employer |
| Employee, no written assignment | Potentially the employee |
| Contractor, no written assignment | Frequently the contractor |
| After assignment | The assignee |
| Joint inventors, no agreement | Each may license the whole |
Contractor gaps are the most common ownership defect found in diligence. Paying for work does not buy the rights in it.
Use present-tense language. "Hereby assigns" operates immediately; "agrees to assign" creates only an obligation. See intellectual property assignment.
Enforcing them
| Requirement | Detail |
|---|---|
| Standing | Owner, or a licensee holding substantially all rights |
| Patent in force | At the time of the infringement |
| Marking | Limits damages if products are unmarked |
| Six-year cap | On past damages |
| Forum | District court, or the ITC for importation |
Rights unenforced are still rights, and enforcement is a separate decision with its own economics. Litigation costs millions and puts the patent at risk of invalidation.
Marking is the cheap step. It starts the damages period without a notice letter and without inviting a declaratory judgment action. See patent marking.
Transferring rights
| Route | Ownership | Fees stay with |
|---|---|---|
| Assignment | Transfers permanently | The buyer |
| Exclusive licence | Stays | The owner |
| Sole licence | Stays | The owner |
| Non-exclusive licence | Stays | The owner |
| Covenant not to sue | Stays | The owner |
Only assignment ends the ongoing obligations. Licensing keeps maintenance fees, enforcement and validity risk with the owner.
Record assignments promptly, in every jurisdiction where rights exist. See assignment search.
Worked example: a granted patent that could not be used
A company patents an improved valve seal and prepares to launch.
| Step | Finding |
|---|---|
| Their patent granted | Valid, claims allowed |
| Assumption | "We own it, so we can sell it" |
| FTO search before launch | Third-party patent on the valve body |
| Their seal requires that body | They infringe |
| Options | Licence, design around, or challenge |
| Their own patent | Still valuable — blocks the other party too |
| Rights they hold | To exclude others from the seal |
| Rights they do not hold | To practise the complete valve |
| Resolution | Cross-licence |
Both patents were valid throughout. Nothing was wrong with either.
The mistake was treating a grant as clearance. Two weeks of FTO work before launch would have found it while design changes were still cheap.
What the claims decide
| Rights are the entitlement | To exclude |
| Claims define the scope | What specifically you can exclude |
| Broad claims | More rights |
| Narrow claims | Fewer, easier to design around |
| Invalidated claims | No rights at all |
Reading the claims is how you find out what rights are worth. A patent with narrow claims nobody would infringe confers rights over nothing anyone wants to do. See patent claim.
Before relying on any patent rights
| Check | Source | Time |
|---|---|---|
| In force? | USPTO Patent Center | 3 min |
| Who owns it? | USPTO Assignment Search | 5 min |
| Remaining term | Front page + PTA + family | 5 min |
| What the claims cover | The claims | Longer |
| Survived any challenge? | PTAB records | 10 min |
Twenty minutes, all free. A substantial share of the patents people worry about turn out to be expired, sold, or narrowed. See patent status.
Rights across IP types
| Patent | Copyright | Trade secret | Trademark | |
|---|---|---|---|---|
| Independent creation a defence | No | Yes | Yes | Sometimes |
| Registration required | Yes | No | None exists | Usually |
| Duration | 20 yrs from filing | Long | While secret | Indefinite |
| Territorial | Yes | Largely | By contract | Yes |
Patents are the only right where independent creation is no defence, which is what makes them strong and what makes freedom-to-operate work necessary.
Patent rights: the checklist
- A patent is a right to exclude, never a right to practise.
- Run freedom-to-operate work separately. A grant is not clearance.
- All five activities count — make, use, sell, offer, import.
- Remember importation reaches goods made abroad.
- Rights are national. File where the market and the manufacturing are.
- Calculate term from the earliest non-provisional filing in the chain.
- Pay the maintenance fees. 58.6% of rights end this way.
- Get written assignments from employees and contractors, in present tense.
- Read the claims. They decide what the rights are actually worth.
- Verify status and ownership before relying on or worrying about any patent.